Evidence map›Paper›PMID 28373196›Full record

ArticleAntimicrobial agents and chemotherapy2017

Development of a Novel Site-Specific Pegylated Interferon Beta for Antiviral Therapy of Chronic Hepatitis B Virus.

Masataka Tsuge, Takuro Uchida, Nobuhiko Hiraga, Hiromi Kan, Grace Naswa Makokha, Hiromi Abe-Chayama, Daiki Miki, Michio Imamura, Hidenori Ochi, C Nelson Hayes and 7 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Interferon Beta Activity Is Modulated via Binding of Specific S100 Proteins.International journal of molecular sciences · 2020
    Article
  10. Article
  11. Host-Directed Antiviral Therapy.Clinical microbiology reviews · 2020
    Review
  12. Review
  13. Article
  14. When Hepatitis B Virus Meets Interferons.Frontiers in microbiology · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 1 country.

Masataka TsugeDepartment of Gastroenterology and Metabolism, Applied Life Sciences, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Takuro UchidaDepartment of Gastroenterology and Metabolism, Applied Life Sciences, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Nobuhiko HiragaDepartment of Gastroenterology and Metabolism, Applied Life Sciences, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Hiromi KanDepartment of Gastroenterology and Metabolism, Applied Life Sciences, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Grace Naswa MakokhaDepartment of Gastroenterology and Metabolism, Applied Life Sciences, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Hiromi Abe-ChayamaDepartment of Gastroenterology and Metabolism, Applied Life Sciences, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Daiki MikiDepartment of Gastroenterology and Metabolism, Applied Life Sciences, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Michio ImamuraDepartment of Gastroenterology and Metabolism, Applied Life Sciences, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Hidenori OchiDepartment of Gastroenterology and Metabolism, Applied Life Sciences, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
C Nelson HayesDepartment of Gastroenterology and Metabolism, Applied Life Sciences, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Rieko ShimozonoPharmaceutical Research Laboratories, Toray Industries. Inc., Kanagawa, Japan.
Tomokatsu IwamuraPharmaceutical Research Laboratories, Toray Industries. Inc., Kanagawa, Japan.
Hideki NarumiPharmaceutical Research Laboratories, Toray Industries. Inc., Kanagawa, Japan.
Tomohiko SuzukiPharmaceutical Research Laboratories, Toray Industries. Inc., Kanagawa, Japan.
Mie KainohPharmaceutical Research Laboratories, Toray Industries. Inc., Kanagawa, Japan.
Tadatsugu TaniguchiDepartment of Molecular Immunology, Institute of Industrial Science, The University of Tokyo, Tokyo, Japan.
Kazuaki ChayamaDepartment of Gastroenterology and Metabolism, Applied Life Sciences, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan chayama@hiroshima-u.ac.jp.
Hiroshima University · JPToray Industries, Inc. (Japan) · JPThe University of Tokyo · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although nucleot(s)ide analogues and pegylated interferon alpha 2a (PEG-IFN-α2a) can suppress hepatitis B virus (HBV) replication, it is difficult to achieve complete HBV elimination from hepatocytes. A novel site-specific pegylated recombinant human IFN-β (TRK-560) was recently developed. In the present study, we evaluated the antiviral effects of TRK-560 on HBV replication

Indexed as

AnimalsAntiviral AgentsCell Line, TumorChemokine CXCL10DNA, CircularDNA, ViralHepatitis B, ChronicHepatitis B Surface AntigensHepatitis B virusHep G2 CellsHumansInterferon-alphaMiceMice, SCIDMice, TransgenicPolyethylene GlycolsAntiviral AgentsChemokine CXCL10CXCL10 protein, humanDNA, CircularDNA, ViralHepatitis B Surface AntigensInterferon-alphapeginterferon alfa-2aPolyethylene GlycolsRecombinant Proteinsantiviral effectgene expressionHBVhuman hepatocyte chimeric mousepegylated interferon beta

Identifiers

PMID28373196
PMCPMC5444133
OpenAlexW2604535074

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.